Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Sales

Cyclerion Therapeutics (CYCN) FCF Margin (2019 - 2025)

Cyclerion Therapeutics has reported FCF Margin over the past 6 years, most recently at 30.17% for Q3 2025.

  • Quarterly results put FCF Margin at 30.17% for Q3 2025, up 85436.0% from a year ago — trailing twelve months through Sep 2025 was 48.16% (up 316524.0% YoY), and the annual figure for FY2024 was 216.65%, changed.
  • FCF Margin for Q3 2025 was 30.17% at Cyclerion Therapeutics, up from 540.86% in the prior quarter.
  • Over the last five years, FCF Margin for CYCN hit a ceiling of 19.93% in Q4 2024 and a floor of 23314.52% in Q1 2021.
  • Median FCF Margin over the past 4 years was 1195.06% (2025), compared with a mean of 3215.02%.
  • Biggest five-year swings in FCF Margin: crashed -2029824bps in 2021 and later skyrocketed 2150931bps in 2022.
  • Cyclerion Therapeutics' FCF Margin stood at 1619.14% in 2021, then tumbled by -118bps to 3535.29% in 2022, then skyrocketed by 101bps to 19.93% in 2024, then plummeted by -251bps to 30.17% in 2025.
  • The last three reported values for FCF Margin were 30.17% (Q3 2025), 540.86% (Q2 2025), and 1195.06% (Q1 2025) per Business Quant data.